Can India test its own medicine? | What is plastic, actually? | The Daily Brief #443

ELI5/TLDR

Two stories from Zerodha’s daily India-business briefing. First: India is the pharmacy of the world for generics but a backwater for inventing drugs, and the chokepoint is clinical trials — specifically the regulator (CDSCO) and the subject expert committees that sit in front of it. Second: with Hormuz disrupting naphtha supply, polymer prices have ripped, which is a good excuse to actually understand what plastic is — long chains of small repeating molecules whose arrangement decides whether you get a carry bag, a PVC pipe, or a Bisleri bottle. Plus three tidbits: imported input costs squeezing manufacturers, three states voting today, and a SEBI grace period on minimum public shareholding.

The Full Story

Pharmacy of the world, but can’t test its own drugs

The setup is Trump’s April 2nd executive order — 100% tariffs on patented drugs imported into the US. India dodged it because Indian pharma doesn’t sell patented drugs; it sells generics. India shipped over $10bn of pharmaceuticals to the US last year, almost entirely copies. The whole industry earned $55bn last year. Merck alone — one company — did $58bn in pharma sales. That ratio is the entire problem stated as a number.

The thing standing between India and drug discovery is clinical trials. Bringing a new drug to market costs roughly $3bn globally, and ~70% of that is trials, not chemistry. India is the world’s third-largest destination for trial registrations — 95,000 on the books, 18,000 added in 2024 — but the volume is misleading. Most of these are late-stage trials run by multinationals that just need bodies, and India offers a vast patient pool at half the per-person cost of the developed world. We are a service layer, not an originator. Between 2008 and 2022, India ran exactly 220 first-in-human phase one trials. China runs over a thousand every year.

The poster case is PopVax, a Hyderabad mRNA startup that designs and manufactures in India but had to fly its trials to Australia. Not because it’s cheaper there — Indian lab work is genuinely cheap — but because the timeline is unworkable. The CDSCO is supposed to clear domestic applications in 30 working days (90 for already-approved-abroad drugs), and if it misses, you’re deemed approved. In practice, the clock resets on any communication, and applications get routed to a subject expert committee before approval. There is often only one such committee per area of medicine — created post-2013 after the Supreme Court hauled up CDSCO for trial lapses — and they’re routinely a six-month bottleneck. After CDSCO clears it, you still need ethics committee sign-off serially (the UK runs these in parallel). Apply in January, first patient walks in by September.

You can’t just import other countries’ data. Indians have at least eight major genetic variations that change how we metabolise drugs. And we carry diseases nobody else is going to develop drugs for — over a quarter of global TB cases, more than a third of global oral cancer cases.

Even when trials do happen, oversight is loose. Ethics committees that should monitor trials are usually passive and untrained. One in eight trials isn’t even registered on the CTRI (Clinical Trials Registry of India), and of those that are, more than three out of four never report results. So we both gate-keep too much at the front and don’t watch carefully enough once a trial is running.

Two reform signals. In January, the government cut licensing requirements for small-batch research and trimmed timelines. In February, Sitharaman announced BioPharma Shakti — Rs 10,000 crore over five years, three goals: 1,000+ accredited trial sites, new pharmaceutical research institutes, a dedicated scientific review cadre at the regulator. Whether this works depends on whether the problem is capacity (fixable by hiring) or structural (the centralised gating model breaks no matter how many people sit at the gate). During COVID, India was clearing trials in a month. The brief’s view: with AI compressing drug design from years to months, India has the CS and biology talent to ride the wave — but only if the trial bottleneck dissolves. Otherwise the molecules will go elsewhere, the way PopVax’s did.

What plastic actually is

Hormuz lit a fuse the brief admits it hadn’t been watching: polymers. Polymer prices up 40%+ in weeks. Naphtha — the main feedstock for global plastic — nearly doubled. Indian PVC pipes up 78% in a single month. In US polyethylene spot markets, sellers’ price offers expire within hours because buyers are scrambling. Asian crackers are going dark; American ones are running flat-out.

The brief then admits something honest: they’ve been throwing around terms like polymer, naphtha, PVC, polyethylene without quite knowing what they mean. So a primer.

A polymer is a long molecule made of one small unit (a monomer) repeated thousands of times. Poly = many, meros = parts. DNA is a polymer (nucleotide monomers). Protein is a polymer (amino acid monomers). Cellulose in tree trunks is a polymer. Plastic is a polymer where the monomer is something like ethylene or propylene. The arrangement of the chains is what decides the material’s behaviour: tightly packed straight chains give you something rigid (PVC pipe), randomly branching chains give you something flexible (carry bag), cross-linked into a web gives you something heat-resistant and tough.

Five plastics plus polyurethane account for 75-80% of global production:

PE (polyethylene): carry bag, milk pouch — the most produced plastic on Earth
PP (polypropylene): heat-resistant food containers
PVC: pipes, window frames, wiring insulation
PET: water bottles; melt-and-spin it and it’s polyester. Your Bisleri and your t-shirt are molecularly identical.
PS (polystyrene): chai cup, thermocol packaging

The first plastics weren’t from oil at all — celluloid (1860s) came from plant cellulose, Bakelite (1907) was synthetic but not petroleum-based. Oil took over because refineries already produced naphtha as a petrol/diesel byproduct, and naphtha cracks beautifully into ethylene and propylene. The economics were irresistible.

The industrial heart of this is the steam cracker — naphtha + steam blasted at 800-870°C for milliseconds, then quenched. A world-scale naphtha cracker burns 3.3 tons of naphtha per ton of ethylene. An ethane cracker (ethane is a natural gas byproduct) is more efficient — 1.3 tons of ethane per ton of ethylene. The US shale revolution gave America cheap domestic ethane, so American petrochemicals rebuilt around ethane. Asia and Europe stayed on naphtha, which means staying on Middle Eastern crude, which means staying exposed to Hormuz. When Hormuz closed, naphtha jumped 74% in two weeks — feedstock now costs more than the polyethylene it makes. Asian crackers go dark; US ethane crackers are having the time of their lives.

Every plastic product starts as a nurdle — a 2-5mm pellet. PE, PP, PVC nurdles look identical but are entirely different materials. Converters buy nurdles and shape them. Plasticisers are added to rigid PVC to make it flexible enough for medical tubing.

The Indian value chain is shaped like a barbell. The top — refinery + cracker + polymer — is a handful of giants: Reliance (Jamnagar is both the world’s largest refinery and one of its largest cracker sites; Reliance alone is ~50% of India’s polymer capacity, runs both ethane and naphtha), IOCL, GAIL, OPAL, Haldia Petrochemicals. The bottom — converters — is 30,000-50,000+ plastic processing units, 85-90% MSMEs. An injection moulding setup costs Rs 10-20 lakh to start. When polymer prices spike, the MSMEs get squeezed. Supreme Industries sits across this — pipes, chairs, LPG cylinders.

Demand: packaging 30%+, construction ~20%, auto ~15%. India uses 11-15 kg of plastic per person per year. The US uses 139 kg. The global average is 28 kg. With 1.4bn people, the growth runway is enormous — and so is the waste runway. Only 9% of all plastic ever made has been recycled. 71% sits in landfills and the environment. More than half of all plastic ever made was made in the last two decades. We’re early in the accumulation curve.

The recycling problem is economic, not technical. Virgin PET in Europe is ~€1,000/ton; recycled PET is ~€1,800. As long as oil is cheap, recycling loses to virgin. The Hormuz spike, perversely, is a windfall for recyclers. And recycling itself isn’t really a loop — polymer chains degrade each pass, so a PET bottle becomes carpet fibre or fleece, which is the end of the line. Downcycling, not recycling. India claims ~60% recycling vs the US at 5-6%, but that’s almost entirely the informal economy: 1.5-4 million rag pickers, kabadiwalas, aggregators, and small recyclers earning Rs 100-500 a day to do work that no government agency does.

The throwaway line that lands: only 4-6% of global crude ends up as plastic, but that sliver has produced “one of the most useful, most ubiquitous, and most environmentally persistent families in human history.”

Tidbits

Imported input costs: Indian manufacturers facing 20-30% jump in raw material costs even after the ceasefire. Dollar up 12% YTD. Electronics components hit hardest. Industry executives expect 5-8% consumer price hikes across categories by Q2.
State elections: Assam, Kerala, Puducherry voted today across 296 seats. Turnout: Assam 84.4%, Puducherry 86.9%, Kerala 75% by 5pm. Results for all five states (incl. TN, WB later this month) in May.
SEBI MPS breather: SEBI won’t initiate penal action against listed companies missing minimum public shareholding deadlines between April 1 and September 30, 2026 — a six-month enforcement holiday triggered by the West Asia crash.

Key Takeaways

India sold $10bn+ of pharma to the US last year, nearly all generics. Indian pharma’s $55bn total < Merck’s $58bn alone.
95,000 trials registered in India; 18,000 in 2024 alone. But only 220 first-in-human phase one trials between 2008-2022. China runs 1,000+ a year.
A new drug costs ~$3bn to bring to market; ~70% of that is clinical testing.
CDSCO timeline: 30 working days for domestic, 90 for already-approved-abroad. In practice, applications stuck 6+ months at the subject expert committee stage. UK runs regulatory and ethics review in parallel; India does them serially.
1 in 8 trials isn’t registered with CTRI. 3 in 4 of those that are never report results.
BioPharma Shakti: Rs 10,000 crore over 5 years for 1,000+ trial sites, new institutes, dedicated review cadre.
Polymer prices +40%+ in weeks; naphtha doubled; Indian PVC pipes +78% in a month.
Top 5 plastics + polyurethane = 75-80% of global production. PE, PP, PVC, PET, PS.
Naphtha cracker: 3.3 tons of naphtha → 1 ton ethylene. Ethane cracker: 1.3 tons ethane → 1 ton ethylene.
Reliance ~50% of India’s upstream polymer capacity; ~30,000-50,000 plastic processing MSMEs at the bottom.
India per-capita plastic use: 11-15 kg. US: 139 kg. Global avg: 28 kg.
9% of all plastic ever made has been recycled; 71% accumulated. Half of all plastic ever made was made in the last two decades.
1.5-4 million Indians make a living from informal plastic recycling.

Claude’s Take

The Daily Brief is at its best when it admits ignorance and then teaches itself in public, which is exactly what happens in the plastic segment — they cop to using “polymer” and “naphtha” without knowing what they meant, and the explainer that follows is genuinely good. The pharma segment is sharper journalism: it doesn’t stop at “India is the pharmacy of the world,” it goes one layer deeper and isolates the specific bottleneck (the subject expert committee created after the 2013 Supreme Court intervention) with a named source (PopVax’s Soham Shankar) and a control case (China’s investigator-initiated trial framework). That’s substance.

The compression is impressive — two genuine explainers plus three tidbits in a 25-minute show without sounding rushed. The framing of “growth story and waste story are the same story” for plastic is the kind of line that does real cognitive work. The connective tissue between Hormuz → naphtha → polymers → MSMEs → PVC pipes is the cleanest causal chain I’ve seen them build.

Two minor flags. The brief uses “Hormuz crisis” and “hormones crisis” interchangeably (auto-transcript artefact, but it appears in the source — worth noting if you re-listen). And the BioPharma Shakti section ends with a “wait and see” that I wish had a sharper take: the framing of “capacity vs structural” is good but they don’t pick a side. My read: it’s structural. Adding 1,000 trial sites doesn’t fix a single subject expert committee per therapy area being the gate; that’s a queueing problem that gets worse with more inputs, not better.

Score: 8/10. Substance density is high, the explainer is genuinely useful (the polymer-arrangement-determines-properties frame is the right mental model), and both segments leave you with named companies, named regulators, and concrete numbers. Loses a point for not pushing harder on the BioPharma Shakti diagnosis.